Jane Street
BMY.RT

Jane Street’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Jane Street’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,968
Closed -$8K – 10005
2020
Q4 		$8K Sell
10,968
-683
-6% -$1.46K ﹤0.01% 7389
2020
Q3 		$26K Sell
11,651
-98,675
-89% -$282K ﹤0.01% 7011
2020
Q2 		$395K Buy
110,326
+82,186
+292% +$297K ﹤0.01% 5427
2020
Q1 		$107K Sell
28,140
-1,827,265
-98% -$6.02M ﹤0.01% 4917
2019
Q4 		$5.58M Buy
+1,855,405
New +$4.82M 0.01% 989

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Jane Street's BMY.RT Position: Q1 2021 in Review

Jane Street sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 10,968 shares — an estimated $8K sold.

Jane Street first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $5.58M in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Jane Street reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Jane Street sold 10,968 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $8K.
  • Jane Street first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Jane Street's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $5.58M in Q4 2019.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Jane Street's 13F filing for Q1 2021, filed 18 May 2021.